Find clinical trials for Adenocarcinoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma

Cancer

Pancreatic Cancer

Stomach Cancer

Colorectal Cancer

Esophageal Cancer

Prostatic Cancer

Adenocarcinoma trials near Nashville, TN, USA:

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Enrolling

Metastatic Pancreatic Ductal Adenocarcinoma

Drug: Gemcitabine

Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences

Nashville, Tennessee, United States and 82 other locations

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Enrolling

PDAC - Pancreatic Ductal Adenocarcinoma

PDAC

Drug: 5-fluorouracil

Drug: leucovorin

Phase 3

Revolution Medicines

Nashville, Tennessee, United States and 38 other locations

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC)....

Active, not recruiting

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Drug: Oxaliplatin

Drug: Fluorouracil

Phase 2

Jazz Pharmaceuticals

Nashville, Tennessee, United States and 22 other locations

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-...

Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NRAS G12D

Drug: ELI-002 2P

Phase 1

Elicio Therapeutics

Nashville, Tennessee, United States and 9 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting

Advanced Upper Gastrointestinal Tract Adenocarcinoma

Drug: Domvanalimab

Drug: Zimberelimab

Phase 3

Arcus Biosciences

Nashville, Tennessee, United States and 203 other locations

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma...

Enrolling

Esophageal Cancer

Gastric Cancer

Biological: LB1908

Phase 1

Legend Biotech

Nashville, Tennessee, United States and 7 other locations

A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Enrolling

Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

Drug: Trastuzumab

Drug: Paclitaxel

Phase 2, Phase 3

ALX Oncology

Nashville, Tennessee, United States and 83 other locations

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...

Enrolling

Non-small Cell Lung Cancer

Drug: Pemetrexed

Drug: Rilvegostomig

Phase 3

AstraZeneca

Nashville, Tennessee, United States and 214 other locations

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

Enrolling

Pancreatic Ductal Adenocarcinoma

Non Small Cell Lung Cancer

Drug: Pemetrexed

Drug: Carboplatin + Pemetrexed

Phase 1, Phase 2

Phanes Therapeutics

Nashville, Tennessee, United States and 5 other locations

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People ca...

Enrolling

Metastatic Gastric Adenocarcinoma

Esophageal Adenocarcinoma

Drug: Trastuzumab

Drug: Capecitabine

Phase 1, Phase 2

Boehringer Ingelheim

Nashville, Tennessee, United States and 49 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Adenocarcinoma in .css-epvm6{white-space:nowrap;}Nashville, TN

Related conditions:

Adenocarcinoma trials near Nashville, TN, USA:

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Find clinical trials for Adenocarcinoma in Nashville, TN